Peptide research profile

Sermorelin

Also known as GHRH(1-29)-NH2 · GRF 1-29 · Formerly Geref

The amidated first 29 amino acids of human GHRH. A branded product was historically used in pediatric GH testing/treatment but was discontinued; modern wellness use is not supported by equivalent evidence.

  • Growth hormone signaling
Human trials2 referencesEducational use

Dosing literacy

Dosing & scaling, explained

The calculator records 200–400 mcg daily fixed doses. Historical pediatric research used weight-based dosing and a specific clinical indication. This is educational source context—not a protocol or recommendation.

Scaling framework

How sourced amounts are organized

  1. Starting pointNot clinically established
    No validated titration window

    There is no regulator-approved starting dose for this research use. A low-looking number is not automatically safe.

  2. Recorded preset200–400 mcg / day
    Calculator library reference

    This is the range represented in the in-app protocol library. It describes the source record; it does not validate the regimen.

  3. Higher exposure400 mcg / day is the upper library row
    Risk and uncertainty increase

    Higher exposure is not established as more effective. Human pharmacokinetic and long-term safety data may be absent.

Drug amount and device markings are different quantities. The calculator converts mass into volume, syringe units, or pen clicks.

Schedule literacy

Patterns described in source material

  • Daily in recorded presets

    The cadence represented by the recorded calculator presets.

  • 30 mcg/kg at bedtime in historical pediatric studies

    Published experiments may use a different route, formulation, timing, or population and should not be treated as interchangeable.

  • No universal schedule

    No single schedule has been validated across products or research contexts.

Clinical context
  • 30 mcg/kg · Once daily at bedtimeHistorical pediatric GHD studiesNot an adult fixed dose

Human dosing exists for historical diagnostic and pediatric contexts, not for modern anti-aging claims.

Research best practices

Storage, handling and interpretation

Lyophilized material

Keep cold, dry, and protected from light according to the manufacturer certificate or validated lab SOP.

After reconstitution

Use sterile technique, refrigerate as validated, and avoid repeated freeze–thaw cycles.

Traceability

Record lot, concentration, preparation date, and the identity/purity documentation used by the lab.

Research orientation

What researchers are exploring

These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.

  • 01

    GH stimulation testing

    Intravenous sermorelin was studied as a pituitary GH-provocation test.

  • 02

    Pediatric growth deficiency

    Historical studies assessed daily subcutaneous therapy in selected children.

  • 03

    Age-related GH physiology

    Small adult studies examined nocturnal GH and IGF-1 responses.

  • 04

    Compounded-use gap

    Current adult wellness claims extend beyond the historical regulated evidence.

Evidence map

What the current evidence can support

Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.

  • Human

    Historical pediatric clinical data

    Daily 30 mcg/kg studies reported increased growth velocity in some prepubertal children.

  • Review

    Diagnostic and treatment review

    The evidence base is old, indication-specific, and does not establish final-height superiority.

  • Human

    Limited older-adult studies

    Small studies measured endocrine and body-composition biomarkers rather than long-term clinical outcomes.

Recorded protocol library

Amounts recorded for Sermorelin

These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.

  • 01

    Dose · lower endpoint

    100 mcg

    Sign in for schedule, duration and source context.

  • 02

    Lower recorded

    200 mcg

    Sign in for schedule, duration and source context.

  • 03

    Dose · upper endpoint

    500 mcg

    Sign in for schedule, duration and source context.

Technical reference

Identity, limitations and unknowns

Molecular profile

Class
GHRH(1-29) receptor agonist
Amino acids
29
Approx. MW
3357.9 Da
Origin / design
Bioactive N-terminal fragment of human GHRH

Important limitations

  • The former approved product was discontinued; compounded preparations differ in oversight.
  • Pediatric weight-based evidence does not validate fixed adult wellness doses.
  • A calculator preset is a recorded research convention, not a recommendation or evidence of clinical benefit.
  • Identity, purity, sterility, and stability can vary substantially outside regulated manufacturing.
  • Route, formulation, and population can make results from one study inapplicable to another use.

Curated sources

2 curated references

  1. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiencyBioDrugs · 1999 · Review
  2. Once daily subcutaneous GHRH therapy accelerates growth in GH-deficient childrenJournal of Clinical Endocrinology & Metabolism · 1996 · Human

Related profiles